Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) for adult ALL, AUTO1/22 for pediatric ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, and AUTO8 for multiple myeloma. It also focuses on developing AUTO5 for peripheral T-cell lymphoma.

Autolus Therapeutics

Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. 

COM:AUTOLUS

Autolus Therapeutics plc

Last Close

2.84

22/11 21:00

Market Cap

1.05B

Beta: -

Volume Today

1.60M

Avg: -

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

revenue

Description

peer of

investor of

competitor of

Metrics